Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Procept Biorobotics Corp (PRCT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: PRCT (1-star) is a SELL. SELL since 1 days. Profits (-3.97%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $76.88
1 Year Target Price $76.88
| 6 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -17.34% | Avg. Invested days 31 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.15B USD | Price to earnings Ratio - | 1Y Target Price 76.88 |
Price to earnings Ratio - | 1Y Target Price 76.88 | ||
Volume (30-day avg) 10 | Beta 1.09 | 52 Weeks Range 47.04 - 103.81 | Updated Date 06/30/2025 |
52 Weeks Range 47.04 - 103.81 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.69 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -36.2% | Operating Margin (TTM) -39.67% |
Management Effectiveness
Return on Assets (TTM) -13.36% | Return on Equity (TTM) -27.62% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2914913782 | Price to Sales(TTM) 12.64 |
Enterprise Value 2914913782 | Price to Sales(TTM) 12.64 | ||
Enterprise Value to Revenue 11.7 | Enterprise Value to EBITDA -24.58 | Shares Outstanding 55328700 | Shares Floating 53205154 |
Shares Outstanding 55328700 | Shares Floating 53205154 | ||
Percent Insiders 4.22 | Percent Institutions 93.05 |
Analyst Ratings
Rating 4 | Target Price 76.88 | Buy 2 | Strong Buy 6 |
Buy 2 | Strong Buy 6 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Procept Biorobotics Corp
Company Overview
History and Background
Procept BioRobotics Corp. is a surgical robotics company focused on advancing patient care by developing, manufacturing, and marketing innovative surgical solutions that address significant unmet needs in urology. The company was founded to improve the standard of care for benign prostatic hyperplasia (BPH).
Core Business Areas
- Aquablation Therapy: Aquablation therapy is Procept BioRobotics' core business, focusing on the treatment of BPH. This therapy uses a heat-free waterjet controlled by robotic technology to resect prostate tissue.
Leadership and Structure
The leadership team includes key executives overseeing various functions such as finance, operations, and marketing. The organizational structure supports its research, development, manufacturing, and commercialization activities.
Top Products and Market Share
Key Offerings
- Aquablation Therapy: Aquablation therapy utilizes a robotically controlled, heat-free waterjet to remove prostate tissue, offering a minimally invasive treatment for BPH. While precise market share data fluctuates, Procept is gaining traction in the BPH treatment market, competing with traditional TURP, laser therapies, and medication. Competitors include Boston Scientific (laser therapies), Olympus (TURP instruments), and various pharmaceutical companies.
Market Dynamics
Industry Overview
The urology market, particularly the segment addressing BPH, is characterized by a growing aging population and increasing patient preference for minimally invasive procedures. The industry is competitive, with ongoing innovation in surgical techniques and technologies.
Positioning
Procept BioRobotics is positioned as an innovator in the BPH treatment market with its Aquablation therapy, offering a unique combination of robotic precision and minimally invasive approach.
Total Addressable Market (TAM)
The TAM for BPH treatment is estimated to be in the billions of dollars annually, encompassing surgical procedures, medications, and other therapies. Procept is positioned to capture a significant portion of this market with its Aquablation technology.
Upturn SWOT Analysis
Strengths
- Innovative Aquablation technology
- Minimally invasive procedure
- Robotic precision
- Growing clinical evidence supporting efficacy
Weaknesses
- Relatively new technology requiring broader adoption
- Higher initial capital investment for hospitals
- Limited long-term clinical data compared to established treatments
Opportunities
- Expanding market penetration in the US and internationally
- Increasing awareness and adoption of Aquablation therapy
- Developing new applications for robotic urology
- Partnerships with hospitals and urology clinics
Threats
- Competition from established BPH treatments (TURP, laser therapies)
- Reimbursement challenges from healthcare providers
- Technological advancements by competitors
- Economic downturn impacting hospital capital expenditures
Competitors and Market Share
Key Competitors
- Boston Scientific (BSX)
- Olympus Corp (OCPNY)
- Teleflex (TFX)
Competitive Landscape
Procept BioRobotics differentiates itself through its robotic Aquablation technology, while competitors rely on established techniques such as TURP and laser therapies. Procept's advantages include precision and minimally invasive approach, while challenges include gaining broader adoption and competing with established players.
Growth Trajectory and Initiatives
Historical Growth: Procept BioRobotics has experienced substantial revenue growth driven by increased adoption of Aquablation therapy.
Future Projections: Analysts project continued revenue growth driven by market penetration, international expansion, and increasing clinical evidence supporting Aquablation therapy.
Recent Initiatives: Recent initiatives include expanding sales and marketing efforts, pursuing regulatory approvals in new markets, and investing in research and development to enhance the Aquablation technology.
Summary
Procept BioRobotics is a surgical robotics company focused on advancing patient care by developing, manufacturing, and marketing innovative surgical solutions that address significant unmet needs in urology. Procept BioRobotics has experienced substantial revenue growth driven by increased adoption of Aquablation therapy. Procept's biggest challenges are gaining broader adoption, longer clinical data and competing with established players. The company should focus on expanding its sales and marketing efforts, pursuing regulatory approvals in new markets, and investing in research and development to enhance the Aquablation technology.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Reports
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Procept Biorobotics Corp
Exchange NASDAQ | Headquaters San Jose, CA, United States | ||
IPO Launch date 2021-09-15 | President, CEO & Director Dr. Reza Zadno Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 756 | |
Full time employees 756 | |||
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. It also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.